Prof Giuseppe Rosano (St George's University Hospital, London, UK) discusses DAPA-HF.

Questions

1. Could you describe DAPA-HF in your own words and what the results tell us?

2. How does this complement existing SGLT2 data?

3. How should DAPA-HF influence clinical practice for use of SGLT2s in both diabetics and non-diabetics patients?

4. With increasing evidence of SGLT2 benefit what further is needed to influence prescribing habits in cardiology?

Filmed on site at ESC 2019 by Radcliffe Cardiology

Videography: Mike Knight & Tom Green

Interviewer: Liam O'Neill